Following latest news of drug failure, Lilly faces investor questions about growth
This article was originally published in Scrip
After announcing its latest clinical disappointment, Eli Lilly will face a number of questions this week about how it is going to remain profitable by cutting more expenses or finding strategic deals that can quickly add to sales.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.